Proteinuria Management Guidelines

First-Line Pharmacologic Therapy

The American College of Cardiology recommends starting with an ACE inhibitor or ARB uptitrated to the maximum tolerated dose as first-line therapy, combined with blood pressure control targeting systolic BP <120-130 mmHg and dietary sodium restriction to <2.0 g/day 1, 2
Renin-angiotensin system (RAS) blockade is the cornerstone of proteinuria management, and should be initiated and uptitrated to the maximum tolerated or allowed daily dose, not merely the dose that achieves blood pressure targets alone 1, 2
The American Society of Nephrology suggests that ACE inhibitor or ARB therapy should not be discontinued if serum creatinine increases modestly and remains stable (up to 30% elevation), as this is an expected hemodynamic effect 1, 2

The American Heart Association recommends targeting systolic blood pressure of 120-130 mmHg using standardized office measurements in most patients with proteinuria 1, 2
For patients with persistent proteinuria >1 g/day, the American Society of Nephrology suggests aiming for blood pressure ≤125/75 mmHg 1
Achieving these lower blood pressure targets typically requires multiple antihypertensive agents in addition to RAS blockade, according to the Journal of the American Society of Nephrology 3

The American Society of Nephrology recommends restricting dietary sodium to <2.0 g/day (<90 mmol/day) in all patients with proteinuria, as this enhances the antiproteinuric effects of pharmacologic therapy 1, 2
The National Kidney Foundation suggests implementing weight normalization, smoking cessation, and regular exercise as synergistic interventions 1

For patients who fail to achieve adequate proteinuria reduction on maximally tolerated ACE inhibitor/ARB therapy, the American Society of Nephrology recommends considering adding mineralocorticoid receptor antagonists (spironolactone or eplerenone), monitoring closely for hyperkalemia 1
The European Renal Association suggests using potassium-wasting diuretics and/or potassium-binding agents to maintain normal serum potassium levels, allowing continuation of RAS blockade 1

For persistent proteinuria >1 g/day despite 3-6 months of optimized supportive care, the American College of Rheumatology recommends considering disease-specific immunosuppressive therapy, such as a 6-month course of corticosteroid therapy for IgA Nephropathy 1, 2
The European League Against Rheumatism suggests initiating combined immunosuppressive treatment with glucocorticoids plus mycophenolic acid analogs for Lupus Nephritis with nephrotic-range proteinuria 4, 5

The American Society of Nephrology recommends that evidence of proteinuria improvement should be apparent by 3 months, with at least 50% reduction by 6 months 1
The Annals of the Rheumatic Diseases suggest targeting proteinuria reduction of ≥25% by 3 months, ≥50% by 6 months, and UPCR <500-700 mg/g by 12 months (complete clinical response) 4